- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02821013
Duur van anti-PD-1-therapie bij gemetastaseerd melanoom (STOP-GAP)
Een gerandomiseerde fase III-studie van de duur van anti-PD-1-therapie bij gemetastaseerd melanoom
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The standard or usual treatment for this disease is to receive treatment with a class of agents known as PD-1 inhibitors, or also with the names anti-PD-1 therapy, immunotherapy and checkpoint inhibitors. PD-1 inhibitors turn on the immune system, so that it can fight the cancer cells in the body. Clinical trials have shown that PD-1 inhibitors (such as pembrolizumab and nivolumab) can shrink tumours and extend the life of patients with melanoma.
To-date, PD-1 inhibitors have been given to patients with melanoma continuously (non-stop), for as long as they remain beneficial, for up to a total duration of 2 years. The 2 year duration was chosen because doctors thought it was reasonable, and has been adopted as the standard or usual duration because it was shown to work in clinical trials. However, some recent observations suggest that PD-1 inhibitors may work just as well if they are given for a shorter time and/or in an intermittent schedule. Intermittent means to take breaks from receiving the drug when, and for as long as, the melanoma is better.
The investigators doing this study are interested to find out whether patients with melanoma live as long when the PD-1 inhibitors are given continuously (non-stop) or in an intermittent schedule (taking breaks). If the two ways of giving the treatment were to be shown to be just as good, benefits of an intermittent schedule may include less clinic visits and side effects, better quality of life, and less cost over time for the Health Care System. However, this is not known at present.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Janet Dancey
- Telefoonnummer: 613-533-6430
- E-mail: jdancey@ctg.queensu.ca
Studie Locaties
-
-
Mildura
-
Victoria, Mildura, Australië, 3500
- Werving
- Mildura Base Public Hospital
-
Contact:
- Jose Leal
-
-
New South Wales
-
Coffs Harbour, New South Wales, Australië, 2450
- Werving
- Coffs Habour Health Campus - NCCI
-
Contact:
- Karen Briscoe
-
Waratah, New South Wales, Australië, 2298
- Werving
- Calvary Mater Newcastle Hospital
-
Contact:
- Ina Nordman
-
Westmead, New South Wales, Australië, 2145
- Werving
- Westmead Hospital
-
Contact:
- Matteo Carlino
-
-
Queensland
-
Birtinya, Queensland, Australië, 4575
- Werving
- Sunshine Coast University Hospital
-
Contact:
- Mary Wagih Azer
- Telefoonnummer: 651 7 520-0200
-
Cairns, Queensland, Australië, 4870
- Werving
- Cairns Hospital
-
Contact:
- Megan Lyle
-
Herston, Queensland, Australië, 4029
- Werving
- Royal Brisbane and Womens Hospital
-
Contact:
- Melissa Eastgate
-
Southport, Queensland, Australië, 4215
- Werving
- Gold Coast University Hospital
-
Contact:
- Marcin Dzienis
-
-
South A.
-
Woodville, South A., Australië, 5011
- Werving
- The Queen Elizabeth Hospital
-
Contact:
- Rachel Roberts-thomson
-
-
Victoria
-
Clayton, Victoria, Australië, 3168
- Werving
- Monash Medical Centre
-
Contact:
- Muhammad Alamgeer
-
Melbourne, Victoria, Australië, 3004
- Werving
- Alfred Hospital
-
Contact:
- Mark Shackleton
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Werving
- Cross Cancer Institute
-
Contact:
- John Walker
- Telefoonnummer: 780 432-8340
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3V 1Z2
- Werving
- BCCA - Surrey
-
Contact:
- Christopher Lee
- Telefoonnummer: 604 930-4017
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Werving
- BCCA - Vancouver
-
Contact:
- Kerry J. Savage
- Telefoonnummer: 2641 604 877-6000
-
Victoria, British Columbia, Canada, V8R 6V5
- Werving
- BCCA - Victoria
-
Contact:
- Tara Baetz
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 5N5
- Werving
- Horizon Health Network
-
Contact:
- M. Saleem Raza
- Telefoonnummer: 506 447-4095
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Werving
- Royal Victoria Regional Health Centre
-
Contact:
- Jason Yu
- Telefoonnummer: 705 728-9090
-
Greater Sudbury, Ontario, Canada, P3E 5J1
- Werving
- Health Sciences North
-
Contact:
- Lacey Pitre
- Telefoonnummer: 705 522-6237
-
Hamilton, Ontario, Canada, L8V 5C2
- Werving
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Contact:
- Elaine McWhirter
- Telefoonnummer: 64609 905 387-9495
-
Kingston, Ontario, Canada, K7L 2V7
- Werving
- Kingston Health Sciences Centre
-
Contact:
- Mihaela Mates
- Telefoonnummer: 77725 613 549-2631
-
Kitchener, Ontario, Canada, N2G 1G3
- Werving
- Waterloo Regional Health Network (WRHN)
-
Contact:
- Gregory J. Knight
- Telefoonnummer: 5262 519 749-4370
-
London, Ontario, Canada, N6A 5W9
- Werving
- London Health Sciences Centre Research Inc.
-
Contact:
- John Lenehan
- Telefoonnummer: 519 685-8640
-
Mississauga, Ontario, Canada, L5M 2N1
- Werving
- Trillium Health Partners - Credit Valley Hospital
-
Contact:
- Sudha Rajagopal
- Telefoonnummer: 5135 905 813-1100
-
Oshawa, Ontario, Canada, L1G 2B9
- Werving
- Lakeridge Health Oshawa
-
Contact:
- Rama Koneru
- Telefoonnummer: 905 576-8711
-
Ottawa, Ontario, Canada, K1H 8L6
- Werving
- Ottawa Hospital Research Institute
-
Contact:
- Xinni Song
- Telefoonnummer: 70208 613 737-7700
-
Toronto, Ontario, Canada, M5G 2M9
- Werving
- University Health Network
-
Contact:
- Marcus Butler
- Telefoonnummer: 5485 416 946-4501
-
Toronto, Ontario, Canada, M4N 3M5
- Werving
- Odette Cancer Centre
-
Contact:
- Teresa M. Petrella
- Telefoonnummer: 416 480-5145
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Werving
- The Research Institute of the McGill University
-
Contact:
- Catalin Mihalcioiu
- Telefoonnummer: 514 934-1934
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Werving
- Allan Blair Cancer Centre
-
Contact:
- Mussawar Iqbal
- Telefoonnummer: 306 766-2691
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Werving
- Saskatoon Cancer Centre
-
Contact:
- Tahir Abbas
- Telefoonnummer: 306 655-2710
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Minimum age 18 or as specified in the Product Monograph and eligible for public funding.
Inclusion Criteria:
-
Histologically confirmed melanoma that is unresectable / metastatic (stage III or stage IV).
-
Eligible to receive treatment with a government approved and publically-funded PD-1 inhibitor, according to the guidance / indications described in the Product Monograph / Provincial Formulary.
-
Patients must have evidence of unresectable / metastatic disease, that is considered evaluable by the investigator and can be followed, but measurable disease is not mandatory.
-
Patients with brain metastases are allowed, provided they are stable according to the following definitions:
- Without evidence of progression for at least four weeks prior to randomization and have no evidence of new or enlarging brain metastases.
- Treated with surgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.
- Treated with stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.
-
Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and health utility questionnaires in either English or French. The baseline assessment must be completed within required timelines, prior to randomization. Inability (lack of comprehension in English or French, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible.
-
Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
-
Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
-
Patients must be randomized prior to the start of, or within 16 weeks from, the initiation of PD-1 inhibitor treatment. For patients who are being randomized before the start of treatment, the PD-1 inhibitor should be started within 5 working days after randomization. Patients who initiate treatment with combination anti-PD-1 and anti-CTLA-4 therapies who experience toxicity may be randomized at the time prior to starting single-agent PD-1 inhibitor. Repeat imaging must be done within 50 days prior to randomization to ensure the patient has no evidence of disease progression
Exclusion Criteria:
- Patients not willing to stop anti-PD-1 therapy, if randomized to the intermittent arm.
- Patients with any contraindications to PD-1 inhibitors, as described in the Product Monograph or Provincial Formulary, and/or not eligible to receive anti-PD-1 therapy.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Arm 1: Intermittent PD-1 Inhibitor therapy
Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer. |
|
|
Actieve vergelijker: Arm 2: Continuous PD-1 Inhibitor therapy
Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Algemeen overleven
Tijdsspanne: 7 jaar
|
7 jaar
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Progressievrije overleving met behulp van RECIST 1.1 / Immuungerelateerde RECIST (irRECIST)
Tijdsspanne: 7 jaar
|
7 jaar
|
|
Responspercentage met behulp van RECIST 1.1 / Immuungerelateerde RECIST (irRECIST)
Tijdsspanne: 7 jaar
|
7 jaar
|
|
Responsduur bij gebruik van RECIST 1.1 / Immuungerelateerde RECIST (irRECIST)
Tijdsspanne: 7 jaar
|
7 jaar
|
|
Aantal en ernst van bijwerkingen bij gebruik van CTCAE v 4.0
Tijdsspanne: 7 jaar
|
7 jaar
|
|
Kwaliteit van leven gemeten door EORTC QLQ-C30
Tijdsspanne: 7 jaar
|
7 jaar
|
|
Economische evaluatie bestaande uit zowel zorggebruik als zorgvoorzieningen gemeten met de EQ-5D-vragenlijst
Tijdsspanne: 7 jaar
|
7 jaar
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie stoel: Xinni Song, Ottawa Hospital Research Institute
- Studie stoel: Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ME13
- UQ-QMP-0001 (Andere identificatie: QMP)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .